Activation of prostaglandin FP and EP2 receptors differently modulates myofibroblast transition in a model of adult primary human trabecular meshwork cells

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 4, 2016, Pages 1816-1825

  Kalouche, Georges ^a,b   Beguier, Fanny ^a   Bakria, Michael ^a   Melik Parsadaniantz, Stéphane ^a   Leriche, Caroline ^b   Debeir, Thomas ^b   Rostène, William ^a   Baudouin, Christophe ^a,c   Vigé, Xavier ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b SANOFI   (France)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

Author keywords

Collagen; Contraction; EP2 receptor; FP receptor; Myofibroblast transition; TGF 2; Trabecular meshwork

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AL 8810; ALPHA SMOOTH MUSCLE ACTIN; BUTAPROST; COLLAGEN; COLLAGEN TYPE 1; FIBRONECTIN; FORSKOLIN; FR180204; GLUCOCORTICOID; LATANOPROST; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN LIGHT CHAIN; PROSTAGLANDIN E RECEPTOR 2; PROSTANOID; RECEPTOR BLOCKING AGENT; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; VINCULIN; ACTA2 PROTEIN, HUMAN; ACTIN; ANTIHYPERTENSIVE AGENT; NEUROPROTECTIVE AGENT; PROSTAGLANDIN E; PROSTAGLANDIN E1; PROSTAGLANDIN F; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR; RNA;

ACTIN POLYMERIZATION; ADULT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; INTRAOCULAR HYPERTENSION; MUSCLE FIBER CONTRACTION; MYOFIBROBLAST; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRABECULAR MESHWORK; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; GLAUCOMA; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ACTINS; ADULT; ALPROSTADIL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; DINOPROST; GLAUCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MYOFIBROBLASTS; MYOSIN LIGHT CHAINS; NEUROPROTECTIVE AGENTS; PROSTAGLANDINS E, SYNTHETIC; PROSTAGLANDINS F, SYNTHETIC; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RNA; SIGNAL TRANSDUCTION; TRABECULAR MESHWORK;

EID: 84963751886     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-17693     Document Type: Article

References (61)

1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040. A systematic review and meta-analysis. Ophthalmology. 2014; 121: 2081-2090.
2. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 1984; 91: 564-579.
3. Grierson I, Howes RC. Age-related depletion of the cell population in the human trabecular meshwork. Eye (Lond). 1987; 1: 204-210.
4. Lütjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW. Quantitative analysis of "plaque material'' between ciliary muscle tips in normaland glaucomatous eyes. Exp Eye Res. 1986; 42: 457-465.
5. Rohen JW, Lütjen-Drecoll E, Flügel C, Meyer M, Grierson I. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp Eye Res. 1993; 56: 683-692.
6. Tektas OY, Lütjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res. 2009; 88: 769-775.
7. Last JA, Pan T, Ding Y, et al. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 2011; 52: 2147-2152.
8. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994; 59: 723-727.
9. Gottanka J, Chan D, Eichhorn M, Lütjen-Drecoll E, Ethier CR. Effects of TGF-b2 in perfused human eyes. Invest Ophthalmol Vis Sci. 2004; 45: 153-158.
10. Shepard AR, Cameron Millar J, Pang IH, Jacobson N, Wang WH, Clark AF. Adenoviral gene transfer of active human transforming growth factor-beta 2 elevates intraocular pressure and reduces outflow facility in rodent eyes. Invest Ophthalmol Vis Sci. 2010; 51: 2067-2076.
11. Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. Exp Eye Res. 2009; 88: 676-682.
12. De Kater A, Shahsafaei A, Epstein DL. Localization of smooth muscle and nonmuscle actin isoforms in the human aqueous outflow pathway. Invest Ophthalmol Vis Sci. 1992; 33: 424-429.
13. Gonzalez JM, Heur M, Tan JCH. Two-photon immunofluorescence characterization of the trabecular meshwork in situ. Invest Ophthalmol Vis Sci. 2012; 53: 3395-3404.
14. Tian B, Gabelt BT, Geiger B, Kaufman PL. The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res. 2009; 88: 713-717.
15. Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014; 5: 1-13.
16. Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol. 2011; 57: 376-379.
17. Zhang K, Zhang L, Weinreb RN. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov. 2012; 11: 541-559.
18. Nilsson SFE, Drecoll E, Lütjen-Drecoll E, et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 2006; 47: 4042-4049.
19. Prasanna G, Carreiro S, Anderson S, et al. Effect of PF-04217329 a prodrug of a selective prostaglandin EP 2 agonist on intraocular pressure in preclinical models of glaucoma. Exp Eye Res. 2011; 93: 256-264.
20. Schachar RA, Raber S, Courtney R, Zhang MA. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0. 005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011; 36: 809-817.
21. Multi-center phase II study assessing the safety and efficacy of DE-117 ophthalmic solution in subjects with primary openangle glaucoma or ocular hypertension (SEE-1). Available at: https: //clinicaltrials. gov/ct2/show/NCT02179008. Accessed October 28, 2015.
22. Safety and efficacy of AGN-210961 ophthalmic solution compared with bimatoprost ophthalmic solution in patients with glaucoma or ocular hypertension. Available at: https: // clinicaltrials. gov/ct2/show/NCT01110499. Accessed October 28, 2015.
23. Richter M, Krauss AHP, Woodward DF, Lütjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003; 44: 4419-4426.
24. El-Shabrawi Y, Eckhardt M, Berghold A, et al. Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone. Eye. 2000; 14: 375-383.
25. Gaton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol. 2001; 119: 1165-1170.
26. Weinreb RN, Lindsey JD, Marchenko G, Marchenko N, Angert M, Strongin A. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Invest Ophthalmol Vis Sci. 2004; 45: 4368-4377.
27. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008; 115: 790-795.
28. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008; 53: S107-S120.
29. Schlötzer-Schrehardt U, Zenkel M, Nüsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002; 43: 1475-1487.
30. Biswas S, Bhattacherjee P, Paterson C. Prostaglandin E2 receptor subtypes, EP1, EP2, EP3 and EP4 in human and mouse ocular tissues-a comparative immunohistochemical study. Prostaglandins Leukot Essent Fatty Acids. 2004; 71: 277-288.
31. Hirata T, Narumiya S. Prostanoid receptors. Chem Rev. 2011; 111: 6209-6230.
32. Kaddour-Djebbar I, Ansari HR, Akhtar RA, Abdel-Latif AA. Species differences in the effects of prostanoids on MAP kinase phosphorylation, myosin light chain phosphorylation and contraction in bovine and cat iris sphincter smooth muscle. Prostaglandins Leukot Essent Fat Acids. 2005; 72: 49-57.
33. Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995; 36: 2461-2465.
34. Vysniauskiene I, Allemann R, Flammer J, Haefliger IO. Vasoactive responses of U46619, PGF2alpha, latanoprost, and travoprost in isolated porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2006; 47: 295-298.
35. Krauss AH, Wiederholt M, Sturm A, Woodward DF. Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle. Exp Eye Res. 1997; 64: 447-453.
36. Wang JW, Woodward DF, Stamer WD. Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow. Invest Ophthalmol Vis Sci. 2013; 54: 4782-4790.
37. Oga T, Matsuoka T, Yao C, et al. Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med. 2009; 15: 1426-1430.
38. Ding WY, Liu L, Wang ZH, et al. FP-receptor gene silencing ameliorates myocardial fibrosis and protects from diabetic cardiomyopathy. J Mol Med. 2014; 92: 629-640.
39. Moore BB, Ballinger MN, White ES, et al. Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. J Immunol. 2005; 174: 5644-5649.
40. Chen CZ, Raghunath M. Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art. Fibrogenesis Tissue Repair. 2009; 2: 7.
41. Polansky JR, Fauss DJ, Zimmerman CC. Regulation of TIGR/ MYOC gene expression in human trabecular meshwork cells. Eye. 2000; 14: 503-514.
42. Wentz-Hunter K, Shen X, Okazaki K, Tanihara H, Yue BYJT. Overexpression of myocilin in cultured human trabecular meshwork cells. Exp Cell Res. 2004; 297: 39-48.
43. O'Brien TE, Metheney CD, Polansky JR. Immunofluorescence method for quantifying the trabecular meshwork glucocorticoid response (TIGR) protein in trabecular meshwork and Schlemm's canal cells. Curr Eye Res. 1999; 19: 517-524.
44. Tamm ER, Siegner A, Baur A, Lütjen-Drecoll E. Transforming growth factor-beta 1 induces alpha-smooth muscle-actin expression in cultured human and monkey trabecular meshwork. Exp Eye Res. 1996; 62: 389-397.
45. Yu AL, Fuchshofer R, Kampik A, Welge-Lüssen U. Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues. Invest Ophthalmol Vis Sci. 2008; 49: 4872-4880.
46. Pattabiraman PP, Rao PV. Mechanistic basis of Rho GTPaseinduced extracellular matrix synthesis in trabecular meshwork cells. Am J Physiol Cell Physiol. 2010; 298: C749-C763.
47. Pattabiraman PP, Maddala R, Rao PV. Regulation of plasticity and fibrogenic activity of trabecular meshwork cells by rho GTPase signaling. J Cell Physiol. 2014; 229: 927-942.
48. Li B, Wang JHC. Application of sensing techniques to cellular force measurement. Sensors. 2010; 10: 9948-9962.
49. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 2007; 127: 526-537.
50. Conti MA, Adelstein RS. Nonmuscle myosin II moves in new directions. J Cell Sci. 2008; 121: 11-18.
51. Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther. 1999; 290: 1278-1284.
52. Meyer-Ter-Vehn T, Gebhardt S, Sebald W, et al. p38 inhibitors prevent TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci. 2006; 47: 1500-1509.
53. Liu Y, Ko JA, Yanai R, et al. Induction by latanoprost of collagen gel contraction mediated by human tenon fibroblasts: role of intracellular signaling molecules. Invest Ophthalmol Vis Sci. 2008; 49: 1429-1436.
54. Thieme H, Schimmat C, Münzer G, et al. Endothelin antagonism: effects of FP receptor agonists prostaglandin F 2a and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006; 47: 938-945.
55. Parekh A, Sandulache VC, Lieb AS, Dohar JE, Hebda PA. Differential regulation of free-floating collagen gel contraction by human fetal and adult dermal fibroblasts in response to prostaglandin E2 mediated by an EP2/cAMP-dependent mechanism. Wound Repair Regen. 2007; 15: 390-398.
56. Parekh A, Sandulache VC, Singh T, et al. Prostaglandin E2 differentially regulates contraction and structural reorganization of anchored collagen gels by human adult and fetal dermal fibroblasts. Wound Repair Regen. 2009; 17: 88-98.
57. Honjo M, Tanihara H, Inatani M, et al. Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001; 42: 137-144.
58. Vasantha Rao P, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001; 42: 1029-1037.
59. Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res. 2013; 37: 1-12.
60. Fuchshofer R, Kuespert S, Junglas B, Tamm ER. The prostaglandin F2a analog fluprostenol attenuates the fibrotic effects of connective tissue growth factor on human trabecular meshwork cells. J Ocul Pharmacol Ther. 2014; 30: 237-245.
61. Choung J, Taylor L, Thomas K, et al. Role of EP2 receptors and cAMP in prostaglandin E2 regulated expression of type I collagen a1, lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts. J Cell Biochem. 1998; 71: 254-263.